摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

cyclohexyl methyl carbonate | 25066-36-8

中文名称
——
中文别名
——
英文名称
cyclohexyl methyl carbonate
英文别名
Methyl-cyclohexyl-carbonat;methyl cyclohexyl carbonate
cyclohexyl methyl carbonate化学式
CAS
25066-36-8
化学式
C8H14O3
mdl
——
分子量
158.197
InChiKey
RVXBJNBDERKLJG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.88
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:a5909a89cdf3cfc82f54b97a770d0002
查看

反应信息

  • 作为产物:
    描述:
    碳酸二甲酯环己醇4-二甲氨基吡啶methyltrioctylphosphonium methyl carbonatepotassium carbonate1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下, 反应 3.5h, 以93%的产率得到cyclohexyl methyl carbonate
    参考文献:
    名称:
    碳酸盐,乙酸盐和酚盐phospho盐在酯交换反应中作为催化剂,用于合成非对称碳酸二烷基酯† •
    摘要:
    甲基三辛基phosph甲基碳酸酯[P 8881 ] + [MeOCO 2 ] -通过烷基的烷基化反应制得。三辛基膦与无毒的碳酸二甲酯。这种盐是合成不同离子液体的方便来源,其中甲基三辛基phosph阳离子与弱碱性阴离子(如碳酸氢根,乙酸根和酚酸根)偶联。在90-220℃下,所有这些化合物[P 8881 ] + X - ; X = MeOCO 2;HOCO 2 ; AcO; PhO是出色的有机催化剂,可用于碳酸二甲酯和碳酸二乙酯与伯醇和仲醇的酯交换反应,包括苯甲醇, 环戊醇, 环己醇,而且在空间上受阻 薄荷脑。优化条件以在高达1 mol%的极低催化剂负载下运行,并获得选择性高达99%且分离产率> 90%的非对称碳酸二烷基酯(ROCO 2 R'; R = Me,Et)。通过同时活化亲电子和亲核反应物的协同机理,对所研究的离子液体的催化性能进行了讨论。
    DOI:
    10.1039/c2ob25447f
点击查看最新优质反应信息

文献信息

  • Lanthanum(III) Isopropoxide Catalyzed Chemoselective Transesterification of Dimethyl Carbonate and Methyl Carbamates
    作者:Manabu Hatano、Sho Kamiya、Katsuhiko Moriyama、Kazuaki Ishihara
    DOI:10.1021/ol102754y
    日期:2011.2.4
    carbonate and much less reactive methyl carbamates with primary (1°), secondary (2°), and tertiary (3°) alcohols was established with the use of a lanthanum(III) complex, which was prepared in situ from lanthanum(III) isopropoxide (3 mol %) and 2-(2-methoxyethoxy)ethanol (6 mol %). In particular, corresponding carbonates and carbamates obtained were of synthetic utility from the viewpoint of the selective protection
    使用镧(III)配合物,建立了反应性较低的碳酸二甲酯和反应性较低的氨基甲酸甲酯与伯(1°),仲(2°)和叔(3°)醇的实际酯交换反应原位由异丙醇镧(III)(3摩尔%)和2-(2-甲氧基乙氧基)乙醇(6摩尔%)原位制备。特别地,从对1°-,2°-和3°-醇的选择性保护和/或脱保护的观点来看,获得的相应的碳酸盐和氨基甲酸酯具有合成用途。
  • Light-induced synthesis of unsymmetrical organic carbonates from alcohols, methanol and CO<sub>2</sub> under ambient conditions
    作者:Sandhya Saini、Nand Kishor Gour、Shafiur Rehman Khan、Ramesh Chandra Deka、Suman L Jain
    DOI:10.1039/d1cc05833a
    日期:——
    The present work describes the first visible light-assisted, metal-free and organic base 1,1,3,3-tetramethyl guanidine (TMG) mediated synthesis of unsymmetrical methyl aryl/alkyl carbonates from the reaction of alcohols, methanol, and CO2 in high to excellent yields under atmospheric pressure and ambient temperature conditions.
    目前的工作描述了第一个可见光辅助、无金属和有机碱 1,1,3,3-四甲基胍 (TMG) 介导的由醇、甲醇和 CO 2的反应合成的不对称甲基芳基/碳酸烷基酯在大气压和环境温度条件下以高到极好的收率。
  • [EN] ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉS DE MÉDICAMENT ANTICORPS
    申请人:PHARMA MAR SA
    公开号:WO2014191578A1
    公开(公告)日:2014-12-04
    Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and (III) R1, R2 and R3 is H, ORa, OCORa, OCOORa, alkyl, alkenyl, alkynyl, etc; R3' is, CORa, COORa, CONRaRb, etc; each of R4 to R10 and R12 is alkyl, alkenyl or alkynyl; R11 is H, CORa, COORa,alkyl, alkenyl or alkynyl, or R11 and R12+N+C atoms to which they are attached may form a heterocyclic group; each of R13 and R14 is H, CORa, COORa, alkyl, alkenyl or alkynyl; each Ra and Rb is H, alkyl, alkenyl, alkynyl, etc.; each dotted line represents an optional additional bond; X is an extending group; AA is an amino acid unit; L is a linker group; w is 0to 12; b is 0 or 1; A bis a moiety comprising at least one antigen binding site, and n is the ratio of the group [D-(X) b -(AA)w-(L)-] to the moiety comprising at least one antigen binding site and is in the range from 1 to 20, are useful in the treatment of cancer.
    药物偶联物公式为 [D-(X)b-(AA)w-(L)-]n-Ab,其中:D 是具有以下公式 (I) 的药物部分或其药物可接受的盐、酯、溶剂化物、互变异构体或立体异构体,其中:A 选自 (II) 和 (III);R1、R2 和 R3 是 H、ORa、OCORa、OCOORa、烷基、烯基、炔基等;R3' 是 CORa、COORa、CONRaRb 等;R4 至 R10 和 R12 各自是烷基、烯基或炔基;R11 是 H、CORa、COORa、烷基、烯基或炔基,或者 R11 和 R12 与它们连接的 N+C 原子可以形成一个杂环组;R13 和 R14 各自是 H、CORa、COORa、烷基、烯基或炔基;Ra 和 Rb 各自是 H、烷基、烯基、炔基等;每个虚线代表一个可选的附加键;X 是一个延伸组;AA 是一个氨基酸单位;L 是一个连接组;w 是 0 到 12;b 是 0 或 1;Ab 是包含至少一个抗原结合位点的部分,n 是 [D-(X)b-(AA)w-(L)-] 组与至少含有一个抗原结合位点的部分的比例,并且范围从 1 到 20,在癌症治疗中是有用的。
  • [EN] DRUG ANTIBODY CONJUGATES<br/>[FR] CONJUGUÉS MÉDICAMENT-ANTICORPS
    申请人:PHARMA MAR SA
    公开号:WO2021214126A1
    公开(公告)日:2021-10-28
    Drug conjugates having formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, (I) wherein D is covalently attached via a hydroxy or amine group to (X)b if any, or (AA)w if any, or to (T)g if any, or (L); that are useful in the treatment of cancer.
    药物偶联物具有公式[D-(X)b-(AA)w-(T)g-(L)-]n-Ab,其中:D是具有以下公式(I)或药用可接受盐、酯、溶剂化物、互变异构体或立体异构体的药物部分,(I)其中D通过羟基或胺基与(X)b(如果有)、或(AA)w(如果有)、或(T)g(如果有)或(L)共价连接;在癌症治疗中有用。
  • RETINOID PRODRUG COMPOUND
    申请人:Muratake Hideaki
    公开号:US20100286427A1
    公开(公告)日:2010-11-11
    A compound represented by the following general formula (I): [R 1 to R 5 represent hydrogen atom, an alkyl group, or a trialkylsilyl group, X represents —NH—CO—, —CO—NH—, —N(COR 6 )—CO—, —CO—N(COR 7 )— (R 6 and R 7 represent a lower alkoxy group, or a carboxy-substituted phenyl group) etc.; and Z represents —Y—CH(R 12 )—COOH, —CHO, —CH═CH—COOH, or —COOR 13 (Y represents a single bond, —CH 2 —, —CH(OH)—, —CO—, —CO—NH—, or —CO—NH—CH 2 —CO—NH—, R 12 represents hydrogen atom or a lower alkyl group, and R 13 represents hydrogen atom, —CH(R 14 )—COOH(R 14 represents hydrogen atom, a lower alkyl group, or hydroxy group), —[CH 2 CH 2 —O] n —CH 2 —CH 2 —OH, —CH 2 —O—[CH 2 CH 2 —O] m —CH 2 —OH, or —[CH(CH 3 )—CO—O] p —CH(CH 3 )—COOH (m, n and p represent an integer of 1 to 100))], a salt thereof or an ester thereof, which has a property of being converted into a retinoid after absorption in vivo.
    由以下一般式(I)表示的化合物: [R1至R5代表氢原子、烷基或三烷基硅基,X代表—NH—CO—、—CO—NH—、—N(COR6)—CO—、—CO—N(COR7)—(R6和R7代表较低的烷氧基或羧基取代的苯基)等;Z代表—Y—CH(R12)—COOH、—CHO、—CH═CH—COOH或—COOR13(Y代表单键、—CH2—、—CH(OH)—、—CO—、—CO—NH—或—CO—NH—CH2—CO—NH—,R12代表氢原子或较低的烷基,R13代表氢原子、—CH(R14)—COOH(R14代表氢原子、较低的烷基或羟基),—[CH2CH2—O]n—CH2—CH2—OH、—CH2—O—[CH2CH2—O]m—CH2—OH或—[CH(CH3)—CO—O]p—CH(CH3)—COOH(m、n和p代表1至100的整数)],其盐或酯,具有在体内吸收后转化为视黄醇类物质的特性。
查看更多